Viva Biotech executes fourth consecutive buyback; 1.60 million shares repurchased on 13 May, cumulative May purchases reach 8.48 million shares

Bulletin Express05-13 19:22

Viva Biotech Holdings disclosed that on 13 May 2026 it repurchased 1.60 million ordinary shares on the Hong Kong Stock Exchange, paying between HKD 1.50 and HKD 1.52 per share. The transaction cost HKD 2.41 million and all repurchased shares are earmarked for cancellation.

Including earlier buybacks on 8, 11 and 12 May, Viva Biotech has acquired 8.48 million shares in the current series at a volume-weighted average price of approximately HKD 1.55 per share. The combined repurchases represent 0.40 % of the company’s issued share capital authorised under the June 2025 mandate, which permits the repurchase of up to 212.84 million shares.

Following the latest transactions, the company’s issued share count remains at 2.13 billion shares, as the repurchased shares have not yet been cancelled. A moratorium on new share issues or transfers of treasury shares is in place until 12 June 2026, in line with Hong Kong listing regulations governing share buybacks.

The board confirms that all repurchases were executed within the scope of the mandate approved on 12 June 2025 and in compliance with applicable listing rules.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119618941?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 19:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119618941","market":"hk","top_or_hot":-1,"title":"Viva Biotech executes fourth consecutive buyback; 1.60 million shares repurchased on 13 May, cumulative May purchases reach 8.48 million shares","media":"Bulletin Express","content":"<p>Viva Biotech Holdings disclosed that on 13 May 2026 it repurchased 1.60 million ordinary shares on the Hong Kong Stock Exchange, paying between HKD 1.50 and HKD 1.52 per share. The transaction cost HKD 2.41 million and all repurchased shares are earmarked for cancellation.</p>\n<p>Including earlier buybacks on 8, 11 and 12 May, Viva Biotech has acquired 8.48 million shares in the current series at a volume-weighted average price of approximately HKD 1.55 per share. The combined repurchases represent 0.40 % of the company’s issued share capital authorised under the June 2025 mandate, which permits the repurchase of up to 212.84 million shares.</p>\n<p>Following the latest transactions, the company’s issued share count remains at 2.13 billion shares, as the repurchased shares have not yet been cancelled. A moratorium on new share issues or transfers of treasury shares is in place until 12 June 2026, in line with Hong Kong listing regulations governing share buybacks.</p>\n<p>The board confirms that all repurchases were executed within the scope of the mandate approved on 12 June 2025 and in compliance with applicable listing rules.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech executes fourth consecutive buyback; 1.60 million shares repurchased on 13 May, cumulative May purchases reach 8.48 million shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech executes fourth consecutive buyback; 1.60 million shares repurchased on 13 May, cumulative May purchases reach 8.48 million shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-13 19:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Viva Biotech Holdings disclosed that on 13 May 2026 it repurchased 1.60 million ordinary shares on the Hong Kong Stock Exchange, paying between HKD 1.50 and HKD 1.52 per share. The transaction cost HKD 2.41 million and all repurchased shares are earmarked for cancellation.</p>\n<p>Including earlier buybacks on 8, 11 and 12 May, Viva Biotech has acquired 8.48 million shares in the current series at a volume-weighted average price of approximately HKD 1.55 per share. The combined repurchases represent 0.40 % of the company’s issued share capital authorised under the June 2025 mandate, which permits the repurchase of up to 212.84 million shares.</p>\n<p>Following the latest transactions, the company’s issued share count remains at 2.13 billion shares, as the repurchased shares have not yet been cancelled. A moratorium on new share issues or transfers of treasury shares is in place until 12 June 2026, in line with Hong Kong listing regulations governing share buybacks.</p>\n<p>The board confirms that all repurchases were executed within the scope of the mandate approved on 12 June 2025 and in compliance with applicable listing rules.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1119618941","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119618941","pubTimestamp":1778671368,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Viva Biotech Holdings disclosed that on 13 May 2026 it repurchased 1.60 million ordinary shares on the Hong Kong Stock Exchange, paying between HKD 1.50 and HKD 1.52 per share. The transaction cost...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物"},"translate_title":"维亚生物连续第四次回购；5月13日回购160万股，5月累计回购达848万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"Viva Biotech Holdings disclosed that on 13 May 2026 it repurchased 1.60 million ordinary shares on the Hong Kong Stock Exchange, paying between HKD 1.50 and HKD 1.52 per share. The transaction cost HKD 2.41 million and all repurchased shares are earmarked for cancellation.\nIncluding earlier buybacks on 8, 11 and 12 May, Viva Biotech has acquired 8.48 million shares in the current series at a volume-weighted average price of approximately HKD 1.55 per share. The combined repurchases represent 0.40 % of the company’s issued share capital authorised under the June 2025 mandate, which permits the repurchase of up to 212.84 million shares.\nFollowing the latest transactions, the company’s issued share count remains at 2.13 billion shares, as the repurchased shares have not yet been cancelled. A moratorium on new share issues or transfers of treasury shares is in place until 12 June 2026, in line with Hong Kong listing regulations governing share buybacks.\nThe board confirms that all repurchases were executed within the scope of the mandate approved on 12 June 2025 and in compliance with applicable listing rules.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119618941","isCrawlerRequest":true}